Precision BioSciences, Inc. (DTIL)

Market Cap	191.55M +99.2%
Revenue (ttm)	45.04M +6,353.0%
Net Income	-38.55M
EPS	-1.59
Shares Out	27.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,498
Open	6.95
Previous Close	6.95
Day's Range	6.64 - 7.20
52-Week Range	3.53 - 9.62
Beta	1.28
Analysts	Strong Buy
Price Target	29.40 (+323.63%)
Earnings Date	Nov 3, 2026

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2019
• Employees: 67
• Stock Exchange: Nasdaq
• Ticker Symbol: DTIL
• Website: https://precisionbiosciences.com

Analyst Summary

According to 5 analysts, the average rating for DTIL stock is "Strong Buy." The 12-month stock price target is $29.4, which is an increase of 323.63% from the latest price.

Price Target

$29.4

(323.63% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 3, 2026

Data Sources Report a data error